Pioneers in genome editing using our proprietary ARCUS® technology to develop potentially curative therapeutics to overcome cancer and cure genetic disease.
From the HBV Cure Workshop to AASLD The Liver Meeting 2026, PBGENE-HBV took the stage in Denver!
At AASLD The Liver Meeting® 2026, ELIMINATE-B lead investigator Man Fung Yuen, MD, PhD, Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, delivered a late-breaking oral presentation featuring new and updated data from 25 patients across 59 administrations in the Phase 1 ELIMINATE-B trial.
At the expected go-forward dose of 0.4 mg/kg, PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients.
Emily B. Harrison, PhD, Director of Translational Sciences, also presented PBGENE-HBV data at the HBV Cure Workshop in Denver.
PBGENE-HBV is the first and only in vivo gene editing therapy designed to eliminate the root cause of chronic hepatitis B, covalently closed circular DNA (cccDNA), to drive viral cure measured by sustained undetectable HBV DNA.
Read the full release, https://t.co/cxSwUuH23L
#PrecisionBioSciences #DTIL #HepatitisB #AASLD
Precision BioSciences, Inc. announced its Q3 2026 clinical program update and quarterly results!
CFO, Naresh Tanna, tells you what you need to know. Read the full press release: https://t.co/1VG9P5L2Mf
#PrecisionBioSciences $DTIL #PBGENEHBV#GeneEditing
Precision BioSciences announced the pricing of a $125 million underwritten offering of common stock and pre-funded warrants at a price of $7.75 per share, a premium to the five-day average closing price.
The deal includes participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, Driehaus Capital Management, as well as other leading life sciences investors.
Precision intends to use the net proceeds to fund the continued research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general corporate purposes.
Read the full release, https://t.co/yFCzlFHh9t
#PrecisionBioSciences $DTIL
Precision BioSciences has been selected to deliver a late-breaking oral presentation on PBGENE‑HBV at AASLD’s The Liver Meeting 2026, taking place November 5–9 in Denver, Colorado.
MF Yuen MD, Ph.D., will present “Durable pgRNA loss in both HBeAg positive and negative patients treated with PBGENE-HBV supports path towards viral cure” on November 8, from 2:15–2:30 p.m. MST.
PBGENE-HBV is our wholly owned in vivo gene editing program being evaluated in the Phase 1 ELIMINATE‑B trial as a potential viral cure for chronic hepatitis B. The program is designed to target and eliminate cccDNA, the source of new infectious HBV particles.
Read the announcement:
https://t.co/sDfy4GeSYQ
#PrecisionBioSciences #PBGENEHBV #ELIMINATEB #HepatitisB #AASLD #TheLiverMeeting #GeneEditing #ARCUS $DTIL
Precision in Japan!
Dr. Sam Collins represented Precision BioSciences at the World Muscle Society conference last week.
We’re grateful for the opportunity to connect with the neuromuscular community as we advance PBGENE‑DMD, our investigational in vivo gene editing program for Duchenne muscular dystrophy.
Read the latest update, https://t.co/taQNJ4UFfN
#PrecisionBioSciences #WorldMuscleSociety #Duchenne #DMD #PBGENEDMD #GeneEditing
September 7 is World Duchenne Awareness Day. Today, we recognize the individuals living with Duchenne muscular dystrophy, as well as the families, caregivers, advocates, and researchers whose dedication strengthens this community every day.
Living with Duchenne brings ongoing challenges that affect not only those diagnosed, but also the people who support them. We are continually inspired by the resilience of individuals and families navigating this journey, the advocates advancing awareness and access, and the researchers working to expand what may be possible for the future.
This year marked an important milestone in Duchenne research: the first participant in the FUNCTION-DMD clinical trial received an investigational gene-editing treatment, PBGENE-DMD, designed to permanently address the underlying cause of his Duchenne muscular dystrophy. Progress like this is only possible because of the individuals and families who choose to participate in research and the clinical teams who partner with them every step of the way.
At Precision BioSciences, we are grateful for the opportunity to learn from and work alongside the Duchenne community with the hope of making a meaningful difference for individuals and families affected by Duchenne.
#WorldDuchenneDay #Duchenne #RareDisease
Precision BioSciences has commenced dosing in the Phase 1/2 FUNCTION‑DMD study, with the first patient receiving PBGENE‑DMD at Arkansas Children’s Hospital.
This milestone marks the first clinical gene‑editing program for Duchenne muscular dystrophy and advances our wholly owned in vivo gene editing approach into the clinic.
PBGENE‑DMD is designed to permanently edit a patient’s own dystrophin gene, with the aim of restoring production of a near full‑length, functional dystrophin protein. The study is enrolling ambulatory boys ages 2–7 with mutations between exons 45 and 55, a key hotspot region representing up to 60% of boys living with Duchenne.
The Precision team is grateful to the patient, their family, and the clinical team for their commitment to advancing this important work. Initial safety data are expected by year-end 2026.
Read the full release, https://t.co/taQNJ4U7qf
#PBGENEDMD #FUNCTIONDMD #Duchenne #DMD #GeneEditing #GeneTherapy #InVivoGeneEditing #ARCUS #RareDisease #ClinicalTrials
Precision BioSciences announced its second quarter 2026 earnings and provided a business update!
CFO, Alex Kelly, tells you what you need to know.
Read the full press release, https://t.co/DOe2PBoabv
#GeneEditing#Biotech $DTIL
How many of the 240 million people living with chronic hepatitis B worldwide will ever receive treatment or know they have it?
On World Hepatitis Day, we’re reminded that hepatitis B remains a leading cause of liver cancer and liver‑related death globally, yet fewer than 5% of people living with chronic HBV are receiving treatment. Most remain undiagnosed and untreated.
At Precision BioSciences, we are striving to advance PBGENE‑HBV, our wholly owned in vivo gene editing program being evaluated in the Phase 1 ELIMINATE‑B trial, and the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA. Elimination of cccDNA results in HBV viral cure because cccDNA is the only source of infectious replication (HBV DNA).
On a day dedicated to hepatitis awareness, we pause to recognize the global burden of hepatitis B and the responsibility of working on approaches that aim to change what is possible for people living with this infection.
For more information, visit https://t.co/oR0pdM6bUS
#HepatitisB #HepatitisDay #HBV
Precision BioSciences has activated a second clinical site at Washington University School of Medicine in St. Louis for the Phase 1/2 FUNCTION‑DMD trial evaluating PBGENE‑DMD in boys ages 2-7 with Duchenne muscular dystrophy.
This expansion marks another step toward assessing PBGENE‑DMD’s potential to restore near full‑length dystrophin and improve long‑term muscle function in patients with mutations between exons 45–55.
Watch our latest DMD update: https://t.co/UDiLrhP4yH
#PBGENEDMD #FUNCTIONDMD #DMD #InVivoGeneEditing #ARCUS #PrecisionBioSciences
At the Jefferies Global Healthcare Conference in New York, the Precision BioSciences leadership team outlined how our proprietary ARCUS in vivo gene editing platform is advancing programs in chronic Hepatitis B and Duchenne muscular dystrophy.
#PrecisionBioSciences#Jefferies $DTIL
"Being added to the Russell 2000 Index broadens our visibility with institutional investors at a pivotal time for Precision BioSciences," said Alex Kelly, Chief Financial Officer of Precision BioSciences. "We are advancing two wholly owned clinical programs, PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, with a cash runway supporting our operations through 2028."
Read the full release here, https://t.co/CPN2zpHauf
#PrecisionBioSciences #Russell2000 $DTIL
Precision BioSciences was honored to join the CureDuchenne FUTURES National Conference in Orlando, participating on the Science Main Stage and in the exhibit hall.
Gary Owens, Senior Director Gene Therapy / Program Lead, at Precision, presented in the Gene Therapy and Gene Editing session, and our team spent time at our booth listening, learning, and connecting with families and clinicians from across the Duchenne community.
$DTIL #PrecisionBioScience #DMD
In case you missed the live event, here are a few of our favorite moments from Precision BioSciences’ recent virtual investor event on Duchenne Muscular Dystrophy (DMD)!
Watch the full conversation to hear the Precision team and external experts discuss PBGENE‑DMD and the upcoming Phase 1/2 FUNCTION‑DMD clinical trial.
Click here for the full replay, https://t.co/UDiLrhP4yH
Precision BioSciences announced its first quarter 2026 earnings and provided a business update!
CFO, Alex Kelly, tells you what you need to know.
Read the full press release, https://t.co/nHvw5a8PpJ
#GeneEditing#Biotech $DTIL
Nothing beats learning side‑by‑side with families.
The Precision BioSciences team recently joined Jett Foundation’s Family Workshop in Salt Lake City, Utah, to listen, learn, and speak with families impacted by Duchenne muscular dystrophy.
We appreciated the opportunity to share more about PBGENE‑DMD and to hear directly from caregivers and clinicians about what matters most as new treatment options move forward.
Learn more about PBGENE-DMD and the Phase 1/2 FUNCTION-DMD study here, https://t.co/AZBj6Y3gXa
Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial application approval in two European countries.
“Expanding ELIMINATE-B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE-HBV, the only gene editing therapy uniquely designed to eliminate cccDNA,” said Cindy Atwell, Chief Development and Business Officer of Precision BioSciences. “Given the strong investigator interest in PBGENE-HBV, especially following the late breaker oral presentation at The Liver Conference 2025, these new trial sites will build on our existing global clinical trial footprint as we advance PBGENE-HBV through the ELIMINATE-B trial.”
To learn more, visit https://t.co/Ry9jmROaJv
$DTIL
Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team presented new preclinical data on PBGENE‑DMD, the company’s in vivo gene editing candidate designed to restore near full‑length dystrophin and potentially benefit boys with mutations between exons 45–55.
As Debra Miller of CureDuchenne noted, “IND clearance for PBGENE‑DMD is an exciting step forward, and we look forward to collaborating to help connect innovation with the patient families we serve.”
Read the full release, https://t.co/AZBj6Y2J7C
Precision BioSciences announced its Q4 and fiscal year 2025 earnings and provided a business update!
CFO, Alex Kelly, tells you what you need to know.
Read the full press release, https://t.co/FBnLNnl2ZB
#GeneEditing#Biotech $DTIL
Join Precision BioSciences for a virtual investor event on March 17 at 9 am ET!
The event features key opinion leaders (KOL), Dr. Aravindhan Veerapandiyan, MD, Pediatric Neurologist and Associate Professor of Pediatrics, Arkansas Children’s Hospital, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy, who will join Precision leaders to discuss:
- The unmet need for DMD patients
- Current treatment landscape
- PBGENE-DMD for Duchenne muscular dystrophy (DMD) and
- An overview of the clinical trial design for the FUNCTION-DMD trial
Register here: https://t.co/mnWr9VXT7Y
Read the full PR: https://t.co/ZM3IZru0Xx
$DTIL